| Market Cap | 18.73M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -10.23M | Forward P/E | -4.91 | EPS next Y | - | 50D Avg Chg | -7.00% |
| Sales | 16.73k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -20.00% |
| Dividend | N/A | Price/Book | 2.96 | EPS next 5Y | - | 52W High Chg | -73.00% |
| Recommedations | 2.00 | Quick Ratio | 0.06 | Shares Outstanding | 1.76M | 52W Low Chg | 30.00% |
| Insider Own | 30.39% | ROA | -99.35% | Shares Float | 1.23M | Beta | - |
| Inst Own | 7.08% | ROE | - | Shares Shorted/Prior | 2.68K/30.30K | Price | 1.08 |
| Gross Margin | 49.99% | Profit Margin | - | Avg. Volume | 746,856 | Target Price | 35.00 |
| Oper. Margin | -8,906.54% | Earnings Date | - | Volume | 14,221 | Change | -0.92% |
Lucy Scientific Discovery Inc., an early stage psychotropics contract manufacturing company, engaged in the research, manufacturing, and commercialization of psychedelic products. The company offers biological raw materials, active pharmaceutical ingredients (APIs), and finished biopharmaceutical products. It also develops and produces highly controlled agricultural grow environments for plant manufacturing and replication applications. The company was formerly known as Hollyweed North Cannabis Inc. and changed its name to Lucy Scientific Discovery Inc. in May 2021. Lucy Scientific Discovery Inc. was incorporated in 2017 and is headquartered in Victoria, Canada.
